| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/29/2010 | CA2765771A1 Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
| 12/29/2010 | CA2765080A1 Method for treating chronic lymphocytic leukemia |
| 12/29/2010 | CA2764860A1 Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof |
| 12/29/2010 | CA2764257A1 Pharmaceutical agent |
| 12/28/2010 | US7858766 Nucleotide sequences coding HEV (hemorrhagic enteritis virus) or EDS (egg drop syndrome virus) capsid proteins for use in vaccinating domestic birds against pathogenic adenoviral infection |
| 12/28/2010 | US7858765 OX40R binding agents |
| 12/28/2010 | US7858762 Expression vector comprising nucleotide sequences coding osmosensitive (os-6) protein for use as tool in enhancing propagation in transgenic bacillus |
| 12/28/2010 | US7858756 Bioassays; kits; ELISA; drug abuse |
| 12/28/2010 | US7858753 Immunoglobulins |
| 12/28/2010 | US7858745 modified deoxycytidine kinase (dCK) mutants with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells; specifically delivered to leukemic blast cells |
| 12/28/2010 | US7858738 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| 12/28/2010 | US7858589 A saponin possessing immune adjuvant activity, derived from Quillaja saponaria; an immunostimulatory oligonucleotide cotaining an unmethylated CpG dinucleotide,wherein the immunostimulatory oligonucleotide is not a part of a DNA vaccine vector |
| 12/28/2010 | US7858588 Oligodeoxynucleic acid modified with (thio)phosphate |
| 12/28/2010 | US7858577 Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2 |
| 12/28/2010 | US7858559 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| 12/28/2010 | US7858345 Of given amino acid sequence; use in diagnosis and treatment of enzootic pneumonia in swine; kits |
| 12/28/2010 | US7858323 Phage microarray profiling of the humoral response to disease |
| 12/28/2010 | US7858300 Methods and compositions to evaluate antibody treatment response |
| 12/28/2010 | US7858298 Contacting with monoclonal antibody which binds to chemokine receptor; blocks fusion and inhibits activation of inflammatory response; inhibiting fusion of HIV-1 to CD4+ cells |
| 12/28/2010 | US7858297 Chemokine-binding protein and methods of use |
| 12/28/2010 | US7858103 Characterizing inflammatory mediator for use in generating antibodies for prevention and treatment of helicobacter infection; immunotherapy |
| 12/28/2010 | US7858102 Compositions for eliciting an immune response against Mycobacterium avium subspecies paratuberculosis |
| 12/28/2010 | US7858101 antigenic composition comprising a purified desialylated group B streptococcus (GBS) type V polysaccharide, covalently linked to a polypeptide carrier moiety that facilitates T cell-dependent antibody responses to GBS type V polysaccharide; use in treating neonatal sepsis and meningitis |
| 12/28/2010 | US7858100 novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new deadly disease in fish; kit for the detection of antibodies reactive with the bacterium |
| 12/28/2010 | US7858099 Method for inducing an immunological response in an animal |
| 12/28/2010 | US7858098 human papillomavirus (HPV); virus-like particles, capsomers; immunogens |
| 12/28/2010 | US7858097 administering recombinant Listeria strain comprising integrated nucleic acid molecule having two open reading frames expressing heterologous antigen and metabolic enzyme |
| 12/28/2010 | US7858096 Mutant forms of meningococcal ADP-ribosylating toxin |
| 12/28/2010 | US7858094 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response |
| 12/28/2010 | US7858093 Single-dose such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles |
| 12/28/2010 | US7858092 Human Fc domain of immunoglobulin, conjugated to a targeting domain comprising a mutant form of blood factor VII, consisting of a substitution of alanine for lysine, or lysine, binds to tissue factor; cancer, rheumatoid arthritis, atherosclerosis |
| 12/28/2010 | US7858091 Insulin-like growth factor binding protein specific monoclonal antibody for use in diagnosis, prevention and treatment of cell proliferative, inflammatory, autoimmune, muscular and vision disorders |
| 12/28/2010 | US7858090 Fibronectin type III (Fn3) for use as diagnostic and treatment tools in gene therapy; identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex |
| 12/28/2010 | US7858089 human monoclonal antibody of the IgG isotype; preventing and treating cardiovascular disorders; specifically binds to the A2 domain of FVIII |
| 12/28/2010 | US7858088 chimeric anti-EGP-2-binding scFv fragment 4D5MOC-A; for treatment of human carcinomas; Pseudomonas exotoxin A |
| 12/28/2010 | US7858087 enhancing the complement mediated cytotoxic activity ofchimeric anti-CD20 monoclonal antibody IDEC-C2B8 (RITUXIMAB) for its target cells by contacting with the antibody; and with a donor complement protein either as fresh plasma/sera or as isolated complement components |
| 12/28/2010 | US7858086 Biopolymer mixture for use in diagnosis, prevention and treatment of acute myeloid leukemia |
| 12/28/2010 | US7858073 By recognising significant variability in the capacity of different isolates of a microbe to activate antigen-presenting cells and T-lymphocytes, a method of evaluating capacity to activate antigen responsive cells and lymphocytes against abnormal microbial colonisation of a mucosal surface |
| 12/28/2010 | US7858070 fusion propteins; homogeneous purity, and unaltered affinity, and can be produced in high yields without the requirement of extensive purification; stable in serum to allow in vivo applications |
| 12/23/2010 | WO2010148386A1 Swine-origin influenza a (h1n1) virus-like particles and methods of use thereof |
| 12/23/2010 | WO2010148335A2 Structured viral peptide compositions and methods of use |
| 12/23/2010 | WO2010148321A1 Slow dissolution method for reconstitution of lyophilized material |
| 12/23/2010 | WO2010148223A2 Anti-vegf antibodies and their uses |
| 12/23/2010 | WO2010148111A1 Nanoemulsion vaccines |
| 12/23/2010 | WO2010148010A1 Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
| 12/23/2010 | WO2010147971A2 Il23 modified viral vector for recombinant vaccines and tumor treatment |
| 12/23/2010 | WO2010147268A1 Vaccine for cervical cancer |
| 12/23/2010 | WO2010147171A1 Chicken-derived anti-lox-1 antibody |
| 12/23/2010 | WO2010147117A1 Peptide and use thereof |
| 12/23/2010 | WO2010146848A1 An antigenic peptide derived from influenza virus and a method for selecting anti-influenza virus antibody |
| 12/23/2010 | WO2010146598A2 Stable, dried rotavirus vaccine, compositions and process for preparation thereof |
| 12/23/2010 | WO2010146511A1 Treatment of overactive bladder |
| 12/23/2010 | WO2010146414A1 Influenza vaccine, composition, and methods of use |
| 12/23/2010 | WO2010146401A1 Method for the purification of protein complexes |
| 12/23/2010 | WO2010146171A1 Novel manner of administering allergen in allergen specific immunotherapy |
| 12/23/2010 | WO2010146150A1 Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders |
| 12/23/2010 | WO2010146094A1 Hla-g alpha 1 multimers and pharmaceutical uses thereof |
| 12/23/2010 | WO2010146058A1 Bace1 inhibitory antibodies |
| 12/23/2010 | WO2010146055A1 Antagonists of beta-catenin for preventing and/or treating neurodegenerative disorders |
| 12/23/2010 | WO2010146043A2 System for the heterologous expression of a viral protein in a ciliate host cell |
| 12/23/2010 | WO2010145895A1 Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases |
| 12/23/2010 | WO2010145017A1 Stimulation of innate immunity with an antigen from bacterial origin |
| 12/23/2010 | WO2010096289A3 Combination therapy using an anti-egfr agent(s) and igf-1r specific antibodies |
| 12/23/2010 | WO2010094981A3 Antibody therapy |
| 12/23/2010 | US20100325744 Non-glycosylated recombinant monovalent antibodies |
| 12/23/2010 | US20100325743 Marks as modifiers of the p53 pathway and methods of use |
| 12/23/2010 | US20100324125 Proteins derived from white spot syndrome virus and uses thereof |
| 12/23/2010 | US20100323024 Puumala virus full-length m segment-based dna vaccines |
| 12/23/2010 | US20100323004 Non-pegylated liposomal doxorubicin triple combination therapy |
| 12/23/2010 | US20100323003 Flaviviridae Mutants Comprising a Deletion in the Capsid Protein for Use as Vaccines |
| 12/23/2010 | US20100323002 Inhibition of melanogenesis and melanoma metastasis with p-amino benzoic acid (paba) |
| 12/23/2010 | US20100322978 Medical composition |
| 12/23/2010 | US20100322975 Anti-bacterial Vaccine Compositions |
| 12/23/2010 | US20100322974 Targeting the histone code as a bacterial strategy for selectively modulating gene expression |
| 12/23/2010 | US20100322972 HCV Vaccines For Chronic HCV Patients |
| 12/23/2010 | US20100322971 Method for producing vaccinal viral strain of a virus of the reoviridae family |
| 12/23/2010 | US20100322970 Modified influenza virus |
| 12/23/2010 | US20100322969 Influenza b viruses having alterations in the hemaglutinin polypeptide |
| 12/23/2010 | US20100322968 Therapeutic agent for cancer |
| 12/23/2010 | US20100322967 B cell tolerance induction |
| 12/23/2010 | US20100322966 Method for allogeneic cell therapy |
| 12/23/2010 | US20100322965 Viral vaccine vectors |
| 12/23/2010 | US20100322964 Bacterial composition and its use |
| 12/23/2010 | US20100322963 Low dose inoculation with tap for anti-tumor immunity |
| 12/23/2010 | US20100322962 Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use |
| 12/23/2010 | US20100322959 Immunogenic composition |
| 12/23/2010 | US20100322958 Modified saccharides |
| 12/23/2010 | US20100322957 Secretion-related bacterial proteins for nlrc4 stimulation |
| 12/23/2010 | US20100322956 Methods and substances for the treatment of alzheimer's |
| 12/23/2010 | US20100322955 Virulence genes, proteins, and their use |
| 12/23/2010 | US20100322954 Enhanced hiv-1 vaccines and methods for their use |
| 12/23/2010 | US20100322953 Lipidated Tumor-Associated Antigens and Immunotherapeutic Compositions |
| 12/23/2010 | US20100322952 Compositions for and methods of enhancing the immune response to antigens |
| 12/23/2010 | US20100322951 Replication-proficient dsRNA capsids and uses thereof |
| 12/23/2010 | US20100322950 Compositions and methods for diagnosis and treatment of tumors |
| 12/23/2010 | US20100322949 Methods for diagnosing and treating astrocytomas |
| 12/23/2010 | US20100322948 Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same |
| 12/23/2010 | US20100322947 Pharmaceutical composition for treating avellino cornea dystrophy comprising an antibody against tgf-beta |
| 12/23/2010 | US20100322946 Multispecific antibodies |
| 12/23/2010 | US20100322945 Immunogenic compounds and protein mimics |